40th Annual Meeting of the American Society of Clinical Oncology: June 5-8, 2004, Ernest N. Morial Convention Center, New Orleans, Louisiana, Annual Meeting Proceedings |
Common terms and phrases
activity adjuvant administered adverse events analysis anthracycline antibody antitumor apoptosis assessed Background baseline biopsy breast cancer breast cancer patients Cancer Center Cancer Institute capecitabine carboplatin carcinoma chemotherapy clinical trial cohort colorectal cancer combination Conclusions correlated cycles diarrhea docetaxel dose level doxorubicin drug effects efficacy EGFR enrolled erlotinib evaluated expression follow-up G-CSF gefitinib gemcitabine gene grade HER2 Hospital Imatinib infusion inhibition inhibitor irinotecan liver median age metastatic metastatic breast cancer Methods mg/m² months neoadjuvant neutropenia observed Oncology oral overall survival oxaliplatin paclitaxel patients pts patients received patients with advanced pharmacokinetic phase II study phase II trial plasma Poster Discussion Poster Session primary prior progression protein pts received randomized range receptor recurrence regimen response rate Results rituximab solid tumors stable disease surgery tamoxifen taxane therapy tolerated toxicity trastuzumab treated treatment tumor tumor cells University vaccine VEGF vinorelbine weeks women